Diet,Botanical Medicine,and Nutraceuticals for Chronic Kidney Disease

Stevens PE , Levin A , Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann Intern Med, 2013; 158:825–830.

Xu J , Murphy SL , Kochanek KD , et al. National Vital Statistics Reports 2018;67. Online document at: www.cdc.gov Accessed April 8, 2019 .

Saran R , Robinson B , Abbott KC , et al. US renal data system 2018 annual data report: Epidemiology of kidney disease in the United States. Am J Kidney Dis, 2019; 73:A7–A8.

Thomas R , Kanso A , Sedor JR . Chronic kidney disease and its complications. Prim Care, 2008; 35:329–344, vii.

Amdur RL , Feldman HI , Gupta J , et al. Inflammation and progression of CKD: The CRIC study. Clin J Am Soc Nephrol, 2016; 11:1546.

Kumar N , Henderson H , Cameron BD , et al. Malnutrition, obesity, and undernutrition in chronic kidney disease. In: Goldsmith D, ed. Oxford Textbook of Clinical Nephrology. Oxford, UK: Oxford University Press, 2018:830–831.

Banerjee T , Crews DC , Tuot DS , et al. Poor accordance to a DASH dietary pattern is associated with higher risk of ESRD among adults with moderate chronic kidney disease and hypertension. Kidney Int, 2019; 95:1433–1442.

Yuzbashian E , Asghari G , Mirmiran P , et al. Adherence to low-sodium Dietary Approaches to Stop Hypertension-style diet may decrease the risk of incident chronic kidney disease among high-risk patients: A secondary prevention in prospective cohort study. Nephrol Dial Transplant, 2018; 33:1159–1168.

Huang X , Jiménez-Moleón JJ , Lindholm B , et al. Mediterranean diet, kidney function, and mortality in men with CKD. Clin J Am Soc Nephrol, 2013; 8:1548–1555.

Di Daniele N , Di Renzo L , Noce A , et al. Effects of Italian Mediterranean organic diet vs. low-protein diet in nephropathic patients according to MTHFR genotypes. J Nephrol, 2014; 27:529–536.

Org WK , Kasiske B , City M . Kidney disease: Improving global outcomes guideline on CKD. 2014. Online document at: www.kdigo.org Accessed June 3, 2019 .

Menon V , Kopple JD , Wang X , et al. Effect of a very low-protein diet on outcomes: Long-term follow-up of the modification of diet in renal disease (MDRD) study. Am J Kidney Dis, 2009; 53:208–217.

Zha Y , Qian Q . Protein nutrition and malnutrition in CKD and ESRD. Nutrients, 2017; 9:pii:E208.

Joshi S , Shah S , Kalantar-Zadeh K . Adequacy of plant-based proteins in chronic kidney disease. J Ren Nutr, 2019; 29:112–117.

Berue S . Vegan protein powder supplements of high biological value. J Ren Nutr, 2012; 22:e39–e41.

Kalantar-Zadeh K , Gutekunst L , Mehrotra R , et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol, 2010; 5:519–530.

McGuire S . Institute of Medicine. 2013. “Sodium intake in populations: Assessment of evidence.” Washington, DC: The National Academies Press, 2013. Adv Nutr, 2014; 5:19–20.

Dharmaratne R . Exploring the role of excess fluoride in chronic kidney disease: A review. Hum Exp Toxicol, 2019; 38:269–279.

Schiffl H . Fluoridation of drinking water and chronic kidney disease: Absence of evidence is not evidence of absence. Nephrol Dial Transplant, 2007; 23:411–411.

Bigotte Vieira M , Magriço R , Viegas Dias C , et al. Caffeine consumption and mortality in chronic kidney disease: A nationally representative analysis. Nephrol Dial Transplant, 2019; 34:974–980.

Oliveira ESM de , Aguiar AS de , Oliveira ESM de , et al. Why eating star fruit is prohibited for patients with chronic kidney disease?. J Bras Nefrol, 2015; 37:241–247.

Shema-Didi L , Sela S , Ore L , et al. One year of pomegranate juice intake decreases oxidative stress, inflammation, and incidence of infections in hemodialysis patients: A randomized placebo-controlled trial. Free Radic Biol Med, 2012; 53:297–304.

Shema-Didi L , Kristal B , Ore L , et al. Pomegranate juice intake attenuates the increase in oxidative stress induced by intravenous iron during hemodialysis. Nutr Res, 2013; 33:442–446.

Shema-Didi L , Kristal B , Sela S , et al. Does pomegranate intake attenuate cardiovascular risk factors in hemodialysis patients?. Nutr J, 2014; 13:18.

Rivara MB , Mehrotra R , Linke L , et al. A pilot randomized crossover trial assessing the safety and short-term effects of pomegranate supplementation in hemodialysis patients. J Ren Nutr, 2015; 25:40–49.

Wu P-T , Fitschen PJ , Kistler BM , et al. Effects of pomegranate extract supplementation on cardiovascular risk factors and physical function in hemodialysis patients. J Med Food, 2015; 18:941–949.

Xu X , Lu Q , Wu J , et al. Impact of extended ginsenoside Rb1 on early chronic kidney disease: A randomized, placebo-controlled study. Inflammopharmacology, 2017; 25:33–40.

Joshwa B , Campbell ML . Fatigue in patients with chronic kidney disease: Evidence and measures. Nephrol Nurs J, 2017; 44:337–343.

Singh RG , Rathore SS , Wani IA , et al. Effects of Salacia oblonga on cardiovascular risk factors in chronic kidney disease patients: A prospective study. Saudi J Kidney Dis Transpl, 2015; 26:61–66.

Collene AL , Hertzler SR , Williams JA , et al. Effects of a nutritional supplement containing Salacia oblonga extract and insulinogenic amino acids on postprandial glycemia, insulinemia, and breath hydrogen responses in healthy adults. Nutrition, 2005; 21:848–854.

Heacock PM , Hertzler SR , Williams JA , et al. Effects of a medical food containing an herbal α-glucosidase inhibitor on postprandial glycemia and insulinemia in healthy adults. J Am Diet Assoc, 2005; 105:65–71.

Ismail TS , Gopalakrishnan S , Begum VH , et al. Anti-inflammatory activity of Salacia oblonga Wall. and Azima tetracantha Lam. J Ethnopharmacol, 1997; 56:145–152.

Huang TH-W , Yang Q , Harada M , et al. Salacia oblonga root improves cardiac lipid metabolism in Zucker diabetic fatty rats: Modulation of cardiac PPAR-α-mediated transcription of fatty acid metabolic genes. Toxicol Appl Pharmacol, 2006; 210:78–85.

Moreillon JJ , Bowden RG , Deike E , et al. The use of an anti-inflammatory supplement in patients with chronic kidney disease. J Complement Integr Med, 2013; 10:pii:/j/jcim.2013.

Shelmadine BD , Bowden RG , Moreillon JJ , et al. A pilot study to examine the effects of an anti-inflammatory supplement on eicosanoid derivatives in patients with chronic kidney disease. J Altern Complement Med, 2017; 23:632–638.

Zhang HW , Lin ZX , Xu C , et al. Astragalus (a traditional Chinese medicine) for treating chronic kidney disease. Cochrane Database Syst Rev, 2014; 10:CD008369.

Arockia Rani PJ , Panneerselvam C . Carnitine as a free radical scavenger in aging. Exp Gerontol, 2001; 36:1713–1726.

Tanphaichitr V , Leelahagul P . Carnitine metabolism and human carnitine deficiency. Nutrition, 1993; 9:246–254.

Katalinic L , Krtalic B , Jelakovic B , et al. The unexpected effects of L-carnitine supplementation on lipid metabolism in hemodialysis patients. Kidney Blood Press Res, 2018; 43:1113–1120.

Argani H , Rahbaninoubar M , Ghorbanihagjo A , et al. Effect of carnitine on the serum lipoproteins and HDL-C subclasses in hemodialysis patients. Nephron Clin Pract, 2005; 101:c174–c179.

Sakurabayashi T , Miyazaki S , Yuasa Y , et al. L-carnitine supplementation decreases the left ventricular mass in patients undergoing hemodialysis. Circ J, 2008; 72:926–931.

Suzuki A , Sakai Y , Hashimoto K , et al. Kinetics of carnitine concentration after switching from oral administration to intravenous injection in hemodialysis patients. Ren Fail, 2018; 40:196–200.

Ahmad S , Robertson HT , Golper TA , et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int, 1990; 38:912–918.

Rathod R , Baig MS , Khandelwal PN , et al. Results of a single blind, randomized, placebo-controlled clinical trial to study the effect of intravenous L-carnitine supplementation on health-related quality of life in Indian patients on maintenance hemodialysis. Indian J Med Sci, 2006; 60:143–153.

Sparks RE . Review of gastrointestinal perfusion in the treatment of uremia. Clin Nephrol, 1979; 11:81–85.

Ranganathan N , Friedman EA , Tam P , et al. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: A 6-month pilot scale trial in Canada. Curr Med Res Opin, 2009; 25:1919–1930.

Ranganathan N , Ranganathan P , Friedman EA , et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther, 2010; 27:634–647.

Bohdan Pechenyak NR , Pechenyak B , Vyas U , et al. Dose escalation, safety and impact of a strain-specific probiotic (Renadyl^™) on stages III and IV chronic kidney disease patients. J Nephrol Ther, 2013; 3:1–9.

Natarajan R , Pechenyak B , Vyas U , et al. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. Biomed Res Int, 2014; 2014:568571.

Sumida K , Molnar MZ , Potukuchi PK , et al. Constipation and incident CKD. J Am Soc Nephrol, 2017; 28:1248.

Lee A , Lambert K , Byrne P , et al. Prevalence of constipation in patients with advanced kidney disease. J Ren Care, 2016; 42:144–149.

Gao Y , Wang G , Li Y , et al. Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3–4 chronic kidney disease. J Nephrol, 2019; 32:265–272.

Mettang M , Weisshaar E . Pruritus: Control of itch in patients undergoing dialysis. Skin Therapy Lett, 2010; 15:1–5.

Giovannetti S , Barsotti G , Cupisti A , et al. Oral activated charcoal in patients with uremic pruritus. Nephron, 1995; 70:193–196.

Pederson JA , Matter BJ , Czerwinski AW , et al. Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal. Ann Intern Med, 1980; 93:446–448.

Tanaka C , Ohtani H , Tsujimoto M , et al. Brief report/drug interactions effects of dosing interval on the pharmacokinetic interaction between oral small spherical activated charcoal and amlodipine in humans. J Clin Pharmacol, 2007; 47:904–908.

Ahmadi F , Abbaszadeh M , Razeghi E , et al. Effectiveness of N-acetylcysteine for preserving residual renal function in patients undergoing maintenance hemodialysis: Multicenter randomized clinical trial. Clin Exp Nephrol, 2017; 21:342–349.

Feldman L , Shani M , Sinuani I , et al. N-acetylcysteine may improve residual renal function in hemodialysis patients: A pilot study. Hemodial Int, 2012; 16:512–516.

Saddadi F , Alatab S , Pasha F , et al. The effect of treatment with N-acetylcysteine on the serum levels of C-reactive protein and interleukin-6 in patients on hemodialysis. Saudi J Kidney Dis Transpl, 2014; 25:66–72.

Shahbazian H , Shayanpour S , Ghorbani A . Evaluation of administration of oral N-acetylcysteine to reduce oxidative stress in chronic hemodialysis patients: A double-blind, randomized, controlled clinical trial. Saudi J Kidney Dis Transpl, 2016; 27:88–93.